Have a personal or library account? Click to login

Acquired haemophilia A: Balancing on the edge of haemostasis – Case series

The Journal of Haemophilia Practice
Volume 12 (2025): Issue 1 (January 2025)
By:
Open Access
|Aug 2025

Figures & Tables

Figure 1.

The course of the inhibitor titre and factor VIII activity level in Case 1, alongside the tapering schedule of haemostatic and immunosuppressive therapy.Each narrowing in the graph represents a dose reduction step. Acenocoumarin was started according to the loading regimen, and subsequently dosages were adjusted based on the International Normalised Ratio (INR).FVIII: factor VIIIrFVIIa: recombinant activated factor VII
The course of the inhibitor titre and factor VIII activity level in Case 1, alongside the tapering schedule of haemostatic and immunosuppressive therapy.Each narrowing in the graph represents a dose reduction step. Acenocoumarin was started according to the loading regimen, and subsequently dosages were adjusted based on the International Normalised Ratio (INR).FVIII: factor VIIIrFVIIa: recombinant activated factor VII

Figure 2.

The course of the inhibitor titre, factor VIII activity level, M-protein, and free kappa light chains in Case 2, alongside the tapering schedule of immunosuppressive and chemotherapy.Each narrowing in the graph represents a dose reduction step.FVIII: factor VIIIMMF: mycophenolate mofetilDara-VCD, daratumumab-bortezomib-cyclophosphamide-dexamethasone
The course of the inhibitor titre, factor VIII activity level, M-protein, and free kappa light chains in Case 2, alongside the tapering schedule of immunosuppressive and chemotherapy.Each narrowing in the graph represents a dose reduction step.FVIII: factor VIIIMMF: mycophenolate mofetilDara-VCD, daratumumab-bortezomib-cyclophosphamide-dexamethasone

Figure 3.

The course of the inhibitor titre and factor VIII activity level in Case 3, alongside the tapering schedule of haemostatic and immunosuppressive therapy.Each narrowing in the graph represents a dose reduction step.FVIII: factor VIIIrFVIIa: recombinant activated factor VII
The course of the inhibitor titre and factor VIII activity level in Case 3, alongside the tapering schedule of haemostatic and immunosuppressive therapy.Each narrowing in the graph represents a dose reduction step.FVIII: factor VIIIrFVIIa: recombinant activated factor VII
DOI: https://doi.org/10.2478/jhp-2025-0008 | Journal eISSN: 2055-3390
Journal RSS Feed
Language: English
Page range: 82 - 86
Published on: Aug 16, 2025
Published by: Haemnet Ltd
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Acquired haemophilia A,
Recombinant FVIIa,
Prothrombin complex concentrate,
Haemostasis,
Comorbidity,
Thromboembolism
Related subjects:
Medicine,
Basic medical science,
Basic medical science, other,
Clinical medicine,
Clinical medicine, other,
Pharmacy,
Pharmacology

© 2025 Marieke J A Verhagen, Sanna R Rijpma, Saskia E M Schols, published by Haemnet Ltd
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 12 (2025): Issue 1 (January 2025)Next article